^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tecvayli (teclistamab-cqyv)

    i
    Other names: JNJ-64007957, JNJ 64007957, JNJ64007957, JNJ 7957, Ab-957, Ab 957, Ab957, JNJ7957
    Company:
    Genmab, J&J
    Drug class:
    CD3 agonist, BCMA inhibitor
    Related drugs:
    1m
    Influence of PPM1D Mutations on Response and Survival Outcomes Following Bispecific Antibody Therapy in Relapsed and Refractory Multiple Myeloma Patients. (PubMed, Biomedicines)
    We conducted a retrospective, single-center study including 27 patients with RRMM who were treated with bsAbs (teclistamab, elranatamab, or talquetamab) between June 2022 and September 2025 and for whom genetic material was available before bsAB treatment. These findings suggest that PPM1D mutations may represent a promising biomarker in patients with RRMM treated with bsAbs. Larger, prospective studies are warranted to validate and further elucidate these observations.
    Journal
    |
    PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D)
    |
    Elrexfio (elranatamab-bcmm) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    1m
    AugMMent: GMMG-HD11/DSMM XXI/64007957MMY3010 (clinicaltrials.gov)
    P3, N=399, Not yet recruiting, University of Heidelberg Medical Center
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • melphalan • Tecvayli (teclistamab-cqyv)
    2ms
    Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma. (PubMed, Oncology (Williston Park))
    T cell-redirecting therapies represent a central pillar in modern oncology, delivering high response rates across hematologic malignancies with expanding roles in earlier treatment settings. Future progress will depend on improving durability, optimizing sequencing, mitigating toxicity, and enhancing real-world deliverability through next-generation and multitarget platforms.
    Review • Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • Epkinly (epcoritamab-bysp) • Elrexfio (elranatamab-bcmm) • Imdelltra (tarlatamab-dlle) • Tecartus (brexucabtagene autoleucel) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • Columvi (glofitamab-gxbm) • cevostamab (RG6160)
    2ms
    Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases. (PubMed, Hemasphere)
    Patients receiving immunoglobulin replacement therapy had a 2.01 lower risk of infections Grade 3 or 4 and a 6.14 lower risk of death. Our findings demonstrate the efficacy of teclistamab in a heavily diseased and pretreated cohort with AL amyloidosis and highlight the necessity of a concomitant immunoglobulin replacement therapy.
    Clinical • Retrospective data • Journal
    |
    NPPB (Natriuretic Peptide B)
    |
    Tecvayli (teclistamab-cqyv)
    2ms
    64007957MMY2022: A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination withnPomalidomide Administered in Alternative Fashion in Participants with RRMM, whonReceived 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy (2025-522114-23-00)
    P1/2, N=35, Not yet recruiting, Odense University Hospital
    New P1/2 trial
    |
    lenalidomide • pomalidomide • Tecvayli (teclistamab-cqyv)
    2ms
    iFIT: Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level (clinicaltrials.gov)
    P3, N=1226, Not yet recruiting, University of Leeds
    New P3 trial
    |
    IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • IFIT2 (Interferon Induced Protein With Tetratricopeptide Repeats 2)
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    2ms
    Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-1. (PubMed, Haematologica)
    Finally, a reduction in BCMA receptor density was observed on bone marrow tumor plasma cells at relapse. Our data highlight the importance of understanding mechanisms of response, resistance, and relapse to teclistamab to optimize T-cell and bispecific antibody activity, advance dosing and sequencing strategies, and inform further evaluation of teclistamab combinations with other anti-myeloma agents and use in earlier lines of treatment to improve patient outcomes.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
    |
    Tecvayli (teclistamab-cqyv)
    2ms
    A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). (clinicaltrials.gov)
    P2, N=30, Recruiting, Shanghai Zhongshan Hospital
    New P2 trial
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Tecvayli (teclistamab-cqyv)
    2ms
    MajesTEC-2: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Apr 2027 --> Oct 2025
    Trial primary completion date
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • pomalidomide • Ogsiveo (nirogacestat) • Tecvayli (teclistamab-cqyv)
    2ms
    TRIlogy-5: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=700, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • ramantamig (JNJ-5322) • Tecvayli (teclistamab-cqyv)
    2ms
    TEAM MDA5: Study of the Efficacy and Safety of a Bispecific Antibody, Teclistamab in Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5 (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New P2 trial
    |
    IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    Tecvayli (teclistamab-cqyv)
    2ms
    A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=40, Completed, Janssen Pharmaceutical K.K. | Active, not recruiting --> Completed
    Trial completion
    |
    Tecvayli (teclistamab-cqyv)